This company has been acquired
La Jolla Pharmaceutical Future Growth
Future criteria checks 4/6
La Jolla Pharmaceutical is forecast to grow earnings and revenue by 59% and 19.8% per annum respectively while EPS is expected to grow by 55.8% per annum.
Key information
59.0%
Earnings growth rate
55.82%
EPS growth rate
| Biotechs earnings growth | 23.7% |
| Revenue growth rate | 19.8% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | n/a |
Recent future growth updates
Recent updates
Innoviva to acquire La Jolla Pharma for $149M including debt
Jul 11We Think La Jolla Pharmaceutical's (NASDAQ:LJPC) Robust Earnings Are Conservative
Nov 11
Our Take On La Jolla Pharmaceutical Company
Jul 02La Jolla Pharmaceutical's (NASDAQ:LJPC) Shareholders Are Down 82% On Their Shares
Mar 11Market Sentiment Around Loss-Making La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Feb 11Industry Analysts Just Upgraded Their La Jolla Pharmaceutical Company (NASDAQ:LJPC) Revenue Forecasts By 18%
Jan 16Should You Take Comfort From Insider Transactions At La Jolla Pharmaceutical Company (NASDAQ:LJPC)?
Jan 05Could The La Jolla Pharmaceutical Company (NASDAQ:LJPC) Ownership Structure Tell Us Something Useful?
Dec 09Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2024 | 77 | 16 | N/A | N/A | 1 |
| 12/31/2023 | 64 | 8 | N/A | N/A | 1 |
| 12/31/2022 | 47 | 1 | N/A | N/A | 1 |
| 6/30/2022 | 46 | 4 | 13 | 13 | N/A |
| 3/31/2022 | 52 | 5 | 14 | 14 | N/A |
| 12/31/2021 | 76 | 20 | 28 | 28 | N/A |
| 9/30/2021 | 74 | 12 | 18 | 18 | N/A |
| 6/30/2021 | 70 | 3 | 7 | 7 | N/A |
| 3/31/2021 | 60 | -16 | -8 | -8 | N/A |
| 12/31/2020 | 33 | -39 | -38 | -38 | N/A |
| 9/30/2020 | 30 | -61 | -48 | -47 | N/A |
| 6/30/2020 | 26 | -79 | -57 | -56 | N/A |
| 3/31/2020 | 26 | -93 | -65 | -65 | N/A |
| 12/31/2019 | 23 | -117 | -86 | -85 | N/A |
| 9/30/2019 | 20 | -137 | -101 | -100 | N/A |
| 6/30/2019 | 18 | -158 | -119 | -118 | N/A |
| 3/31/2019 | 14 | -181 | -141 | -139 | N/A |
| 12/31/2018 | 10 | -199 | -155 | -152 | N/A |
| 9/30/2018 | 6 | -193 | -153 | -146 | N/A |
| 6/30/2018 | 2 | -168 | -136 | -127 | N/A |
| 3/31/2018 | 1 | -142 | -118 | -109 | N/A |
| 12/31/2017 | N/A | -115 | -94 | -85 | N/A |
| 9/30/2017 | 0 | -101 | -83 | -78 | N/A |
| 6/30/2017 | 0 | -96 | -78 | -75 | N/A |
| 3/31/2017 | 0 | -85 | -70 | -68 | N/A |
| 12/31/2016 | 1 | -78 | -61 | -59 | N/A |
| 9/30/2016 | 1 | -65 | -50 | -49 | N/A |
| 6/30/2016 | 2 | -54 | -40 | -39 | N/A |
| 3/31/2016 | 1 | -49 | N/A | -33 | N/A |
| 12/31/2015 | 1 | -42 | N/A | -25 | N/A |
| 9/30/2015 | 1 | -37 | N/A | -22 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LJPC's forecast earnings growth (59% per year) is above the savings rate (1.9%).
Earnings vs Market: LJPC's earnings (59% per year) are forecast to grow faster than the US market (14.9% per year).
High Growth Earnings: LJPC's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: LJPC's revenue (19.8% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: LJPC's revenue (19.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LJPC's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/08/22 09:29 |
| End of Day Share Price | 2022/08/19 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
La Jolla Pharmaceutical Company is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Keay Nakae | Chardan Capital Markets, LLC |
| Reni Benjamin | H.C. Wainwright & Co. |
| Eun Kyung Yang | Jefferies LLC |